·Transparent drive checks closed and suspended units, four found non-compliant
To further strengthen the commitment towards making Himachal a drug free State as envisioned under the Statewide anti-chitta drive launched by the Chief Minister on 15th November, a comprehensive inspection of 20 pharmaceutical manufacturing units was carried out across the State on Wednesday. The drive was jointly conducted by Himachal Pradesh Police and the State Drugs Control Administration.
The inspection was conducted across six districts, which includes two units each in Una and Bilaspur, four units in Solan, one in Sirmaur, one in police district Nurpur and ten pharmaceutical manufacturing units in police district Baddi. Inspections in five other units were underway till the time of reporting.
The primary objective of this campaign was to curb the illegal manufacture of prohibited drugs and prevent their unlawful diversion. The team inspected units that were closed, permanently or temporarily suspended and those that had surrendered their licenses. Recent intelligence inputs indicate that certain closed or inactive pharmaceutical units could be misused for clandestine production of illegal drugs, including counterfeit, fake-branded and psychotropic substances.
The inspection exercise was conducted in a transparent and well-coordinated manner with the active cooperation of police personnel and drug inspectors. The teams verified the status of manufacturing licenses, scrutinized documents, audited stock records and carried out detailed physical inspections. Warehouses and production areas were thoroughly searched to ensure complete compliance. The entire process was carried out with full transparency and fairness.
During this special drive, irregularities were detected in four such units. Necessary legal action, as per the prescribed provisions, is being initiated against them.
Himachal Pradesh Police continues to uphold its zero-tolerance policy against drugs and remains fully committed to preventing any misuse, illegal manufacturing or unlawful diversion within pharmaceutical units.
